LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Multicenter study evaluating target attainment of anti-Factor Xa levels using various enoxaparin prophylactic dosing practices in adult trauma patients.

    Chanas, Tyler / Gibson, Gabrielle / Langenstroer, Elizabeth / Herrmann, David J / Carver, Thomas W / Alexander, Kaitlin / Chui, Sai Ho Jason / Rein, Lisa / Ha, Michael / Maynard, Kaylee M / Bamberg, Kristen / O'Keefe, Mary / O'Brien, Marisa / Gonzalez, Mariela Cardona / Hobbs, Brandon / Pajoumand, Mehrnaz / Peppard, William J

    Pharmacotherapy

    2024  Volume 44, Issue 3, Page(s) 258–267

    Abstract: Study objective: Enoxaparin is standard of care for venous thromboembolism (VTE) prophylaxis in adult trauma patients, but fixed-dose protocols are suboptimal. Dosing based on body mass index (BMI) or total body weight (TBW) improves target prophylactic ...

    Abstract Study objective: Enoxaparin is standard of care for venous thromboembolism (VTE) prophylaxis in adult trauma patients, but fixed-dose protocols are suboptimal. Dosing based on body mass index (BMI) or total body weight (TBW) improves target prophylactic anti-Xa level attainment and reduces VTE rates. A novel strategy using estimated blood volume (EBV) may be more effective based on results of a single-center study. This study compared BMI-, TBW-, EBV-based, and hybrid enoxaparin dosing strategies at achieving target prophylactic anti-Factor Xa (anti-Xa) levels in trauma patients.
    Design: Multicenter, retrospective review.
    Data source: Electronic health records from participating institutions.
    Patients: Adult trauma patients who received enoxaparin twice daily for VTE prophylaxis and had at least one appropriately timed anti-Xa level (collected 3 to 6 hours after the previous dose after three consecutive doses) from January 2017 through December 2020. Patients were excluded if the hospital-specific dosing protocol was not followed or if they had thermal burns with > 20% body surface area involvement.
    Intervention: Dosing strategy used to determine initial prophylactic dose of enoxaparin.
    Measurements: The primary end point was percentage of patients with peak anti-Xa levels within the target prophylactic range (0.2-0.4 units/mL).
    Main results: Nine hospitals enrolled 742 unique patients. The most common dosing strategy was based on BMI (43.0%), followed by EBV (29.0%). Patients dosed using EBV had the highest percentage of target anti-Xa levels (72.1%). Multiple logistic regression demonstrated EBV-based dosing was significantly more likely to yield anti-Xa levels at or above target compared to BMI-based dosing (adjusted odds ratio (aOR) 3.59, 95% confidence interval (CI) 2.29-5.62, p < 0.001). EBV-based dosing was also more likely than hybrid dosing to yield an anti-Xa level at or above target (aOR 2.30, 95% CI 1.33-3.98, p = 0.003). Other pairwise comparisons between dosing strategy groups were nonsignificant.
    Conclusions: An EBV-based dosing strategy was associated with higher odds of achieving anti-Xa level within target range for enoxaparin VTE prophylaxis compared to BMI-based dosing and may be a preferred method for VTE prophylaxis in adult trauma patients.
    MeSH term(s) Adult ; Humans ; Enoxaparin ; Anticoagulants ; Venous Thromboembolism/drug therapy ; Blood Coagulation Tests ; Burns
    Chemical Substances Enoxaparin ; Anticoagulants
    Language English
    Publishing date 2024-01-08
    Publishing country United States
    Document type Multicenter Study ; Journal Article
    ZDB-ID 603158-4
    ISSN 1875-9114 ; 0277-0008
    ISSN (online) 1875-9114
    ISSN 0277-0008
    DOI 10.1002/phar.2904
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Activated prothrombin complex concentrate for warfarin reversal in traumatic intracranial hemorrhage.

    Carothers, Chancey / Giancarelli, Amanda / Ibrahim, Joseph / Hobbs, Brandon

    The Journal of surgical research

    2017  Volume 223, Page(s) 183–187

    Abstract: Background: Patients with traumatic intracranial hemorrhage (TIH) anticoagulated with warfarin are at an increased risk of mortality. Fresh frozen plasma (FFP) and vitamin K have been the standard treatment for warfarin reversal; however, guidelines now ...

    Abstract Background: Patients with traumatic intracranial hemorrhage (TIH) anticoagulated with warfarin are at an increased risk of mortality. Fresh frozen plasma (FFP) and vitamin K have been the standard treatment for warfarin reversal; however, guidelines now recommend the use of prothrombin complex concentrate (PCC) for warfarin reversal in patients with life-threatening bleeding. Our protocol uses one vial (∼1000 units) of activated PCC (aPCC) for warfarin reversal, regardless of the weight or presenting international normalized ratio (INR). The purpose of this study was to determine the safety and efficacy of using fixed, low-dose aPCC for warfarin reversal in patients with TIH.
    Methods: This was a retrospective chart review that included patients with an Abbreviated Injury Scale Head score of ≥3, TIH, and initial INR ≥ 1.5 on warfarin. Patients aged <18 years and those with no repeat INR were excluded. The primary outcome was to compare the percentage of patients with INR ≤ 1.4 after receiving aPCC versus FFP within 24 hours.
    Results: Eighty-nine patients were in the FFP group and 31 patients in the aPCC group. The INR was reversed more effectively in the aPCC group compared with the FFP group (90.3% versus 69.7%, P = 0.029). The median time (hours) to reversal was also significantly shorter in the aPCC group compared with the FFP group (3.75 versus 6.75, P = 0.003). However, there was no difference in mortality (35.5% aPCC versus 22.2% control, P = 0.162) or incidences of thrombosis.
    Conclusion: Fixed, low-dose aPCC is safe and more effective at reversing the effects of warfarin than FFP in patients with TIH.
    MeSH term(s) Aged ; Aged, 80 and over ; Blood Coagulation Factors/therapeutic use ; Female ; Humans ; International Normalized Ratio ; Intracranial Hemorrhage, Traumatic/drug therapy ; Male ; Retrospective Studies ; Warfarin/antagonists & inhibitors
    Chemical Substances Blood Coagulation Factors ; prothrombin complex concentrates (37224-63-8) ; Warfarin (5Q7ZVV76EI)
    Language English
    Publishing date 2017-12-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80170-7
    ISSN 1095-8673 ; 0022-4804
    ISSN (online) 1095-8673
    ISSN 0022-4804
    DOI 10.1016/j.jss.2017.11.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Hypocalcemia in trauma patients receiving massive transfusion.

    Giancarelli, Amanda / Birrer, Kara L / Alban, Rodrigo F / Hobbs, Brandon P / Liu-DeRyke, Xi

    The Journal of surgical research

    2016  Volume 202, Issue 1, Page(s) 182–187

    Abstract: Background: Massive transfusion protocol (MTP) is increasingly used in civilian trauma resuscitation. Calcium is vital for coagulation, but hypocalcemia commonly occurs during massive transfusion due to citrate and serum calcium chelation. This study ... ...

    Abstract Background: Massive transfusion protocol (MTP) is increasingly used in civilian trauma resuscitation. Calcium is vital for coagulation, but hypocalcemia commonly occurs during massive transfusion due to citrate and serum calcium chelation. This study was conducted to determine the incidence of hypocalcemia and severe hypocalcemia in trauma patients who receive massive transfusion and to compare characteristics of patients with severe versus nonsevere hypocalcemia.
    Materials and methods: This was a retrospective study of trauma patients who received massive transfusion between January 2009 and November 2013. The primary outcome was the incidence of hypocalcemia (ionized calcium [iCa] < 1.12 mmol/L) and severe hypocalcemia (iCa < 0.90 mmol/L). Secondary outcomes included calcium monitoring, calcium replacement, and correction of coagulopathy.
    Results: There were 156 patients included; 152 (97%) experienced hypocalcemia, and 111 (71%) had severe hypocalcemia. Patients were stratified into iCa ≥ 0.90 (n = 45) and iCa < 0.90 (n = 111). There were no differences in demographics or baseline laboratories except the severe hypocalcemia group had higher baseline activated partial thromboplastin time (29.7 [23.7-50.9] versus 25.8 [22.3-35.9], P = 0.003), higher lactic acid (5.8 [4.1-9.8] versus 4.0 [3.1-7.8], P = 0.019), lower platelets (176 [108-237] versus 208 [169-272], P = 0.003), and lower pH (7.14 [6.98-7.28] versus 7.23 [7.14-7.33], P = 0.019). Mortality was higher in the severe hypocalcemia group (49% versus 24%, P = 0.007). Patients in the iCa < 0.90 group received more blood products (34 [23-58] versus 22 [18-30] units, P < 0.001), and calcium chloride (4 [2-7] versus 3 [1-4] g, P = 0.002), but there was no difference in duration of MTP or final iCa. Neither group reached a median iCa > 1.12.
    Conclusions: Hypocalcemia is common during MTP, and vigilant monitoring is warranted. Research is needed to effectively manage hypocalcemia during massive transfusion.
    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Blood Transfusion/methods ; Female ; Humans ; Hypocalcemia/diagnosis ; Hypocalcemia/epidemiology ; Hypocalcemia/etiology ; Incidence ; Male ; Middle Aged ; ROC Curve ; Retrospective Studies ; Severity of Illness Index ; Transfusion Reaction ; Wounds and Injuries/therapy ; Young Adult
    Language English
    Publishing date 2016-05-01
    Publishing country United States
    Document type Comparative Study ; Journal Article
    ZDB-ID 80170-7
    ISSN 1095-8673 ; 0022-4804
    ISSN (online) 1095-8673
    ISSN 0022-4804
    DOI 10.1016/j.jss.2015.12.036
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top